Login to Your Account

Clinic Roundup

Tuesday, January 10, 2012
• BioCryst Pharmaceuticals Inc., of Birmingham, Ala., reported long-term results from the extension phase of its randomized Phase IIb study of BCX4208 added to allopurinol in patients with gout who had failed to reach the serum uric acid OR sUA therapeutic goal of < 6 mg/dL on allopurinol alone. The company said the results confirmed that BCX4208 was generally safe and well tolerated, and sustained sUA control over time.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription